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ABSTRACT The development of clustered, regularly interspaced, short palindromic repeats (CRISPR)/
CRISPR-associated (Cas) technologies promises a quantum leap in genome engineering of model organisms.
However, CRISPR-mediated gene targeting reports in Drosophila melanogaster are still restricted to a few
genes, use variable experimental conditions, and vary in efficiency, questioning the universal applicability of
the method. Here, we developed an efficient two-step strategy to flexibly engineer the fly genome by
combining CRISPR with recombinase-mediated cassette exchange (RMCE). In the first step, two sgRNAs,
whose activity had been tested in cell culture, were co-injected together with a donor plasmid into transgenic
Act5C-Cas9, Ligase4 mutant embryos and the homologous integration events were identified by eye fluores-
cence. In the second step, the eye marker was replaced with DNA sequences of choice using RMCE enabling
flexible gene modification. We applied this strategy to engineer four different locations in the genome, in-
cluding a gene on the fourth chromosome, at comparably high efficiencies. Our data suggest that any fly








Reverse genetics is currently booming with the establishment of TALEN-
and CRISPR-mediated genome engineering (Hsu et al. 2014; Sander and
Joung 2014; Joung and Sander 2013). In particular, the CRISPR/Cas9
technology appears to efficiently and specifically introduce double strand
DNA breaks in the genome of the organism, which can then be utilized
to either introduce point mutations by error-prone nonhomologous
end-joining (NHEJ) or integrate heterologous DNA into the chromo-
some using the homology-directed repair (HDR) pathway (Sander and
Joung 2014). In Drosophila, CRISPR-induced NHEJ has mainly been
utilized to mutate genes that result in a visible, easily scored phenotype,
such as white eyes or yellow body color, or to mutate GFP transgenes
(Gratz et al. 2013a; Sebo et al. 2014; Ren et al. 2013; Bassett et al. 2013).
Mutants in genes with no visible phenotype required PCR screening for
their identification; therefore, high mutagenesis rates are important,
which might be difficult to achieve at all positions in the fly genome
(Kondo and Ueda 2013; Yu et al. 2013, 2014; Gokcezade et al. 2014; Port
et al. 2014). Recently, this bottleneck was addressed by applying
CRISPR-induced HDR to insert an attP-site together with a visible
marker into the gene of interest (Baena-Lopez et al. 2013; Gratz et al.
2014; Xue et al. 2014). In some cases the visible marker was flanked by
FRT or loxP sites allowing its excision to only leave one attP site (and
one loxP or FRT site) within the gene. This attP site enables the
introduction of any given DNA sequence into the gene of interest
(Baena-Lopez et al. 2013; Gratz et al. 2014; Xue et al. 2014). However,
the efficiency of reporter integration was rather low (Baena-Lopez et al.
2013) and only determined at a single genomic locus (Gratz et al. 2014;
Xue et al. 2014), leaving the general applicability to the Drosophila
genome an open question. Port et al. (2014) reported an alternative
CRISPR-mediated HDR strategy by using a transgenic single guide
RNA (sgRNA) source and crossing it to a transgenic Cas9 source. This
method also enabled targeting of somatic cells in a tissue-specific man-
ner, but it required the generation of new transgenic sgRNA lines for
every locus (Port et al. 2014).
Here, we have developed a highly flexible two-step genome engi-
neering platform that combines CRISPR-mediated HDR with FC31
recombinase-mediated cassette exchange (RMCE). In the first step,
CRISPR is applied to integrate a splice acceptor and an SV40 terminator
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together with a 3xP3-dsRed eye reporter. This enables both the efficient
identification of the targeted event and the creation of a strong loss of
function allele. In the second step, two flanking attP sites are utilized to
replace the inserted DNA by any DNA of choice using RMCE, an
established standard technology in Drosophila (Venken et al. 2011).
Together, this allows flexible cassette exchange to freely manipulate
the gene of interest. We successfully applied this method to four differ-
ent locations in the genome and efficiently generated several allele
variants, including a conditional allele, from a single targeting event.
Our streamlined CRISPR/Cas9-based and RMCE-based strategies make
it practical to flexibly engineer anyDrosophila gene of choice for a broad
range of applications within approximately 3 months.
MATERIALS AND METHODS
Fly strains and genetics
All fly work, unless otherwise stated, was performed at 25 under
standard conditions. The Lig4[169] null allele (McVey et al. 2004)
was obtained from the Bloomington Drosophila Stock Center, and
y[1], M(Act5c-Cas9, [w+]) in M(3xP3-RFP.attP)ZH-2A, w[1118] was
a gift from Fillip Port and Simon Bullock before publication (Port et al.
2014). Both markers (w+ and 3xP3-RFP) were removed by crossing to
heat-shock-Cre. The y[1], M(Act5C-Cas9)ZH-2A, w[1118] flies were
recombined with Lig4[169] to obtain y[1], M(Act5C-Cas9)ZH-2A,
w[1118], Lig4[169].
Cell culture
Drosophila Schneider 2 (S2) cells stably expressing myc-Cas9 from a
ubiquitin promoter were a gift from Klaus Förstemann before publi-
cation (Böttcher et al. 2014). S2 cells were cultured in Schneider’s
Drosophilamedium supplemented with 10% fetal calf serum (Life Tech-
nologies) and penicillin/streptomycin (GE Healthcare). sgRNA activities
were tested by transfecting 1 mg sgRNA per 24 wells into the myc-Cas9
cells using Fugene HD (Promega), followed by DNA extraction and
a T7-Endonuclease I assay (see supplied protocol for details).
Plasmids
CC6-U6-gRNA_hsp70-Cas9 plasmid was a gift from Peter Duchek
before publication (Gokcezade et al. 2014). pJET1.2-STOP-dsRed:
attP1 and splicing acceptor (SA) were amplified with primers XZ82
and XZ83, SV40 terminator with XZ84 and XZ85, and attP2 with
XZ88 and XZ89 from DNA extracted from a MiMIC fly line (Venken
et al. 2011); 3xP3-dsRed was amplified from a fosmid fly line (Langer
et al. 2010) with primers XZ86 and XZ87. These fragments were cloned
into pLR-HD plasmid by Golden Gate cloning (Cermak et al. 2011).
This assembled attP1-SA-STOP-SV40-3xP3-dsRed-attP2 cassette was
amplified with primers XZ195 and XZ196 and blunt cloned into
pJET1.2 to generate pJET1.2-STOP-dsRed. Because this STOP-dsRed
cassette is flanked by two BsmBI sites, it can be easily assembled with
both homology arms (Figure 3A): each homology arm of approximately
1 kb was amplified from genomic DNA of the target genotype with
Phusion polymerase (NEB) and blunt-end cloned into pJET1.2
(CloneJET PCR Cloning Kit, Thermo Scientific). Primers used to am-
plify the homology arms have a 59 BsmBI site enabling Golden Gate
assembly with the STOP-dsRed cassette. All primers used are listed in
Supporting Information, Table S1. pBS-donor-backbones pBS-GGAC-
TTCT, pBS-GGAC-ATGC, and pBS-CGGA-GTGC were constructed
by linearizing pBluescript with KpnI and SacII, followed by amplification
with primer pairs XZ150 and XZ151, XZ156 and XZ151, and XZ161
and XZ162, respectively, and re-ligation. The generated pBS-donor-
backbones harbor two BsmBI sites for donor plasmid assembly.
pJET1.2-STOP-dsRed, pJET1.2-HA-left, pJET1.2-HA-right, and an ap-
propriate pBS-backbone were assembled to the pBS-donor vector by
Golden Gate cloning. attB plasmids FRT-2xTY1-FRT-V5 and 2xTY1-
V5 fragments were synthesized as gBlocks (IDT) and cloned into the
attB plasmid for all three reading frames. For construction of CC6-U6-
gRNA_hsp70-Cas9-sgRNA1,3,4,7 and 9 the CC6-U6-gRNA_hsp70-
Cas9 vector was cut with BbsI (NEB) and the annealed sgRNA targeting
oligos were cloned into it. The vas-FC31(3xP3-EGFP.attB) plasmid was
obtained from Johannes Bischof (Bischof et al. 2007). The attB site was
removed by digestion with SpeI, followed by re-ligation.
All plasmids for embryo injections were purified with PureLink
HiPure Plasmid Midiprep Kit (Life Technologies). Oligos are listed in
Table S1.
sgRNA synthesis
The sgRNA dsDNA template was produced using overlap PCR with
a small amount of a common sgRNA scaffold primer, a shorter sgRNA
amplification primer, and a sgRNA gene-specific primer that includes
the T7 promoter (Figure 3C) (Böttcher et al. 2014). All sgRNA primer
sequences are listed in Table S1. The PCR product was cleaned by
Qiagen MinElute kit (Qiagen). The sgRNAs were transcribed with
T7-MEGAshortscript Kit (Life Technologies) and purified with
MEGAclear Transcription Clean-Up Kit (Life Technologies).
Embryo injection
Preblastoderm embryos of the appropriate genotype were de-chorionated
and injected with a FemtoJet apparatus (Eppendorf) using self-pulled
glass needles (Harvard Apparatus) under standard conditions at room
temperature. Injected embryos were kept for 2 d at 18 and the hatched
larvae were collected and grown at 25. For step 1 injections, pBS-donor
plasmid, two sgRNAs, and (optionally) the CC6-U6-gRNA_hsp70-Cas9
plasmid were mixed and diluted in water. Lig4[169] embryos were
injected with CC6-U6-gRNA_hsp70-Cas9 plasmid (100 ng/ml) and
pBS-donor plasmid (500 ng/ml). y[1], M(Act5C-Cas9)ZH-2A, w[1118],
Lig4[169] embryos were injected with both sgRNAs (60–70 ng/ml each)
and pBS-donor plasmid (500 ng/ml). For step 2 injections, the attB
plasmid (150 ng/ml) was mixed with vasa-FC31 plasmid (200 ng/ml).
Immunolabeling of IFMs: Hemi-thoraces of adult Drosophila were
prepared and stained as described (Weitkunat and Schnorrer 2014).
Rabbit anti-Salm was used at 1:50 (Kühnlein et al. 1994), mouse anti-
Flag (Sigma), mouse anti-V5 (Abcam), and rhodamine phalloidin
(Invitrogen) were all used at 1:500. Nuclei were visualized by embed-
ding in Vectashield plus DAPI (Vector Laboratories) and images were
acquired on a Zeiss LSM780 confocal and processed with FIJI and
Photoshop.
Detailed Drosophila genome engineering protocol
by CRISPR-RMCE
1. CRISPR-sgRNA design and donor plasmid cloning 10 d
1.1 Verify sequence of the planned targeting regions for the
sgRNAs in the fly strain used and in the S2 cells by sequencing
to identify potential polymorphisms compared with the pub-
lished sequence.
1.2 For designing the sgRNA targeting sites, choose one of the
web tools (Beumer and Carroll 2014). We used an interface
designed by the Zhang laboratory (http://crispr.mit.edu).
1.3 sgRNA production
1.3.1 Generate the dsDNA template for sgRNA in vitro tran-
scription as described by Böttcher et al. (2014).
2410 | X. Zhang, W. H. Koolhaas, and F. Schnorrer
1.3.2 Transcribe sgRNA by T7-MEGAshortscript Kit (AM1354;
Life Technologies). Use 150- to 250-ng template for a 20-ml
reaction at 37 overnight.
1.3.3 Purify sgRNA by MEGAclear Transcription Clean-Up Kit
(Life Technologies). Follow the manufacturer’s protocol and,
in step 3, add an equal volume of 100% ethanol to the sample.
1.3.4 Check the sgRNA integrity on a gel and measure the con-
centration using a photometer (Nanodrop, Thermo Scien-
tific). The expected yield is 50–100 mg, which is enough for
the S2 cell assay and the fly injections.
1.4 sgRNA activity assay in S2 cells
1.4.1 Grow S2 cells in Schneider medium with 10% FCS (Life
Technologies) to 5–10 · 106 cells/ml at 25.
1.4.2 Dilute cells to 0.7 · 106/ml and plate 1 ml cells in S2
medium with 10% FCS per well in a 24-well plate for each
transfection.
1.4.3 Prepare the transfection mix by diluting 1 mg sgRNA in 50
ml serum free medium and 4 ml Fugene HD mix plus 46 ml
serum free medium, mix both, and incubate for 45 min at
room temperature.
1.4.4 Add the Fugene/RNA mix to each well and mix gently by
pipetting.
1.4.5 After 48–60 hr at 25, harvest the cells and extract the
genomic DNA by QIAamp DNA mini kit (Qiagen).
1.4.6 For the T7 Endonuclease I assay, amplify an approximately
500-bp fragment, which harbors the sgRNA targeting site
with Phusion polymerase (NEB), and denature and anneal
the PCR product as described by Zhang et al. (2014).
1.4.7 Mix on ice 10 ml annealed PCR product with 10 ml T7
Endonuclease I master mix [2 ml T7 endonuclease I buffer,
0.5 ml T7 endonuclease I (5 units, NEB) and 7.5 ml water].
1.4.8 Digest at 37 for 15–20 min using a PCR machine and load
on 1.5% agarose gel immediately.
1.4.9 Estimate the efficiency of different sgRNAs by comparing
the band intensities of the digested and nondigested bands.
1.5 Generation of donor plasmid (can be performed in parallel
with steps 1.3 and 1.4 to save time)
1.5.1 Amplify left and right homology arms (approximately 1 kb,
start as close to the sgRNA cutting site as possible) with Phusion
polymerase (NEB) from the fly strain that is used for HDR and
clone them into pJET-1.2 according to the CloneJET PCR Clon-
ing Kit (Thermo Scientific).
1.5.2 Assemble the Golden Gate Cloning reaction [50 ng pBS-
backbone, 80 ng pJET1.2-HA-left, 80 ng pJET1.2-HA-right,
80 ng pJET1.2-STOP-dsRed, 1.5 ml 10x T4 ligation buffer, 1 ml
BsmBI (NEB, R0580), 1 ml T4 ligase (NEB, M0202) add water
to 15 ml].
1.5.3 Ligate in PCR machine using the following cycles: 15 cycles
of 37, 5 min/16, 10 min/37, 15 min/50, 5 min/80, and
5 min/4.
1.5.4 Assemble the Plasmid-safe nuclease reaction (15 ml ligation
reaction 3 ml 10· Plasmid-safe buffer 1.2 ml 25 mM ATP 1 ml
Plasmid-safe nuclease (Epicentre) 9.8 ml water).
1.5.5 Incubate at 37 for 60 min in PCR machine and transform
5–10 ml in bacteria. Most growing colonies will be correct.
2. Fly step 1 - CRISPR-mediated HDR 6 wk
2.1 Inject 600–800 Act5C-Cas9, lig4[169] embryos with pBS-
donor (500 ng / ml) and two sgRNAs (each 60–70 ng/ml, target-
ing close to the chosen homology arms). Collect at least 50
fertile mosaic G0 flies.
2.2 Cross G0 flies individually (at least 50 vials) either to yw flies
or appropriate balancer flies and screen all the F1 progeny for
fluorescent red eyes using a fluorescent binocular (Leica
MZ16-FA). Keep track of how many independent G0 founders
lead to how many F1 carrier flies.
2.3 Generate stocks from an individual F1 carrier by crossing to
balancer flies resulting in an isogenized stock for the engineered
chromosome. Verify the targeting event by PCR and sequencing.
3. Fly step 2: FC31-mediated RMCE 6 wk
3.1 Inject a “generic” plasmid generated by Venken et al. (2011) or
this study or your own custom-made gene-specific attB plasmid
(150 ng/ml) mixed with vasa-FC31 plasmid (200 ng/ml) into ap-
proximately 200 embryos from an amplified stock generated at 2.3.
3.2 Cross G0 flies individually to an appropriate balancer and
screen all F1 progeny for nonfluorescent eyes using a fluores-
cent binocular (Leica MZ16-FA).
3.3 Generate stocks from an individual F1 carrier by crossing to
balancer flies, resulting in an isogenized stock for the engi-
neered chromosome. Verify the correct orientation of the
RMCE by PCR (will be 50%).
RESULTS
Strategy overview
We aimed to develop a versatile and efficient strategy to modify the
Drosophila genome that would allow various genome modifications
such as the introduction of single point mutations, protein tags, exon
deletions, or other desired changes in the gene of choice. Despite the
suggested higher efficiency of CRISPR/Cas9-induced HDR as com-
pared with Zn-finger–induced or TALEN-induced HDR, the identifi-
cation of successfully targeted carrier flies is still a limiting step in the
process. PCR-based screening or melting curve analysis methods require
DNA extraction (Beumer et al. 2013a), which can be inconvenient for
efficient stock generation. Therefore, we decided to develop a two-step
strategy as illustrated in Figure 1, which enables efficient identification of
the carrier flies and allows entirely flexible genome engineering. In the
first step, we insert a 3xP3-dsRed marker enabling easy identification of
the HDR event. A strong splice acceptor, followed by STOP codons and
an SV40 polyA terminator, precedes the dsRed cassette. The inserted
DNA is flanked by two attP sites in opposite orientations, a strategy that
we adapted from the popular MiMIC system (Venken et al. 2011). If this
cassette is inserted into an intron or replaces an endogenous exon, then
it results in truncated mRNA of the targeted gene. Thus, step 1 can be
used to create a loss-of-function allele (Figure 1).
In the second step, RMCE is applied to replace the DNA between
both attP sites by any DNA of choice, leaving a minimal scar of two attR
sites, preferably in introns. RMCE has been used very efficiently in the
MiMIC system, demonstrating that attR sites in introns generally do not
interfere with gene function (Venken et al. 2011). Hence, our strategy
enables the generation of various alleles, like a defined point mutation,
a tagged allele, an exon replaced by a tag, or a conditional allele, from
a single HDR carrier (Figure 1). This strategy should allow flexible edit-
ing of any Drosophila gene within approximately 3 months (Figure 2).
CRISPR design and cloning
In step 1, we aimed to insert a STOP-3xP3-dsRed cassette flanked by
two attP sites using a donor plasmid (Figure 1). Because the same
strategy should be applicable to any gene, we established a single-step
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Golden Gate protocol to assemble the STOP-dsRed donor plasmid
containing approximately 1-kb homology arms on each side, which
has been shown to be of sufficient length for efficient HDR (Beumer
et al. 2013b) and can be easily amplified by PCR. Cloning of the ho-
mology arms into the donor vector is thus very straightforward and
takes only a few days for the gene of choice (Figure 3A, see Materials
and Methods). This donor vector is the template for the HDR in step 1.
In step 2, RMCE exchanges the STOP-dsRed by any sequence
located between two attB-sites in a provided donor plasmid (Figure 1).
RMCE works very reliably and a large collection of plasmids to tag
genes or insert reporters for various applications is available (Venken
et al. 2011). These plasmids are fully compatible with our step 2 de-
sign. We have generated additional “generic” attB plasmids that can be
used to tag any gene with a 2xTY1-V5 tag or to engineer a conditional
allele using an FRT flanked 2xTY1 cassette followed by a V5 tag
(Figure 3B). Flp-mediated deletion of the 2xTY1 cassette will lead to
a frame shift and thus can be used to create loss-of-function clones at
very high efficiency, as the flip-out will occur in cis (Hadjieconomou
et al. 2011). The TY1 tag is a convenient affinity tag (Sarov et al.
2012). We have generated both constructs in all three reading frames.
Figure 1 A two-step method to flexi-
bly engineer the fly genome. Overview
of the two-step procedure. In step 1, a
donor vector consisting of two attP sites
(P), a splice acceptor (SA), and STOP
codons (yellow box, black asterisk) fol-
lowed by an SV40 polyadenylation signal
(pA) and a 3xP3dsRed marker are in-
serted on Cas9 cleavage with two
sgRNAs. The orange coding exon is
excised. In step 2, FC31-mediated
RMCE inserts any DNA sequence be-
tween the two attB sites (B). Examples
for various engineered exons are given,
resulting in attR sites (R) in introns. F
stands for FRT.
Figure 2 Two-step genome engineering timeline.
Schematic overview of the major steps of the genome
engineering procedure. Details are provided inMaterials
and Methods.
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CRISPR activity assay in cell culture
Many search algorithms exist to predict sgRNA target sequences for
a given gene region (Beumer and Carroll 2014). However, to date there
is no simple way of confirming if any of the predicted sgRNAs work
efficiently. We developed such a selection assay to be able to only inject
effective sgRNAs into fly embryos. We designed 12 different sgRNAs
targeting different regions in the salm gene and synthesized the sgRNAs
by a standard PCR and in vitro transcription reaction (Figure 3C). These
sgRNAs were then individually transfected into Cas9 expressing S2 cells
(Böttcher et al. 2014), and their cleavage efficiency was determined with
a simple T7-Endonuclease I assay (see Materials and Methods) (Zhang
et al. 2014). On average, approximately half of the tested sgRNAs work
efficiently in this assay (Figure 3D), strongly suggesting that such a pre-
selection test is useful to improve the in vivo success rates.
Step 1: HDR in Lig4 mutant embryos
To test the efficiency of inserting our STOP-dsRed cassette, we
designed three donor constructs targeting different regions in the salm
gene (Figure 4A): the first, deleting parts of exon 1; the second, insert-
ing the cassette into intron 1; and the third, deleting exon 3. For each
construct approximately 1-kb homology arms were cloned in the
STOP-dsRed donor vector. We injected the STOP-dsRed donor as
circular plasmid together with two plasmids each containing a U6
promoter-driven sgRNA verified in S2 cells and a hsp70-Cas9 source
(seeMaterials and Methods). We injected into Ligase4mutant embryos,
which were reported to exhibit a higher rate of HDR than wild-type
embryos (Beumer et al. 2013a,b). We injected between 700 and 1500
embryos for each of the three constructs and were able to recover 11
red-eyed F1 carriers from two independent founders for the first intron
construct and 72 red-eyed F1s from four independent founders for the
third exon deletion construct (Table 1). This demonstrated that our
strategy works in principle, but because we failed to recover the first
exon deletion allele, we wanted to further improve the efficiency by
using a different Cas9 source.
Step 1: Transgenic Cas9 improves HDR efficiency
A number of transgenic Cas9 flies have been generated recently, and
some of which have been used successfully (Ren et al. 2013; Xue et al.
2014; Gratz et al. 2014; Port et al. 2014). To test whether a transgenic
Cas9 source is more efficient for HDR than a source from an injected
plasmid, we targeted the same positions as above, but now using
Act5C-Cas9, Lig4 flies. For this, we recombined an Act5C-Cas9 transgene
Figure 3 Cloning scheme and sgRNA
activity tests. (A) Single-step Golden
Gate assembly scheme of the STOP-
dsRed donor vector cloned into a mod-
ified pBluescript backbone. (B) Scheme
of the “generic” attB plasmids used in
our study. A simple cloning step is suf-
ficient to generate any gene-specific
attB plasmid that can be used to re-
place an excised exon. (C) sgRNA syn-
thesis scheme. (D) sgRNA activity assay
of 12 different sgRNAs in S2 cells. PCR
result with (bottom) or without (middle)
T7-Endonuclease I treatment are shown.
Digested products are marked by arrow
heads and effective sgRNAs are marked
by a red asterisk. C are controls without
sgRNA.
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expressing Cas9 ubiquitously, including maternally in the germline (Port
et al. 2014), with the Lig4[169] null allele. Additionally, we removed the
white and 3xP3dsRed markers from the Act5C-Cas9 transgene to obtain
a Act5C-Cas9, Lig4[169] chromosome that is useful for the injection of
our donor plasmids (see Materials and Methods). We injected 700
Act5C-Cas9, Lig4[169] embryos with two in vitro transcribed sgRNAs
targeting either the first exon, the first intron, or the third exon of salm
(using the same sgRNA target sequences as used above). We obtained
one, nine, and four independent founders producing 13, 54, and 59 F1
carriers, respectively, demonstrating that all three locations were tar-
geted successfully with frequencies between 3% and 14% per fertile G0
(Table 1). To verify that the targeted insertion occurred correctly, we
tested a total of nine independent carriers from the three locations by
PCR and sequencing. We were able to confirm that all of these tar-
geted correctly by “ends-out” homologous recombination. We did not
detect any “ends-in” insertions, which were reported to occur occa-
sionally (Yu et al. 2014) (Figure S1 shows salm[1st intron-dsRed] as an
example).
The first step of our gene-targeting strategy inserts a strong splice
acceptor followed by a STOP cassette into the gene and thus should
terminate transcription at this position. By design, the salm[1st exon-
dsRed] allele additionally has a deleted ATG. As expected, the salm[1st
exon-dsRed] allele is homozygous lethal, as well as lethal in trans to
salm[1], demonstrating that we created a strong salm loss-of-function
allele (Figure 5A). The salm[1st intron-dsRed] allele harbors an inser-
tion in the first intron (Figure 4A). This allele is also homozygous
lethal, and lethal in trans to salm[1], suggesting that the splice acceptor
and STOP cassette are used efficiently to create a strong loss-of-
function allele (Figure 5A). The salm[3rd exon-dsRed] allele only dele-
tes the last 36 amino acids of the long SalmPA isoform, including
10 amino acids of the last zinc finger (Figure 4A). This allele is ho-
mozygous viable (Figure 5A). Taken together, these data suggest that
our CRISPR-mediated step 1 strategy works efficiently to isolate tar-
geted carrier flies at a practical frequency for routine use. Conveniently,
these step 1 alleles are generally loss-of-function alleles if the insertion
is located within the gene.
Figure 4 Engineering of the salm gene.
(A) Step 1 engineering of the salm gene.
The genomic salm organization is de-
picted with coding exons in orange.
The sgRNA targeting sites are indicated
by red arrows and the resulting salm[1st
exon-dsRed], [1st intron-dsRed] and [3rd
exon-dsRed] alleles are shown. (B) Step
2 engineering of the salm gene. RMCE
products of the salm[1st intron-dsRed]
with three different exon cassettes are
shown.




















salm[1st exon-dsRed] Lig42/2 sgRNA1 + sgRNA3 1500 396 166 ND 0 0 ND
salm[1st intron-dsRed] Lig42/2 sgRNA3 700 171 149 ND 2 11 ND
salm[3rd exon-dsRed] Lig42/2 sgRNA7 + sgRNA9 1500 312 150 ND 4 72 ND
salm[1st exon-dsRed] Act5C-Cas9, Lig42/2 sgRNA1 + sgRNA3 700 124 48 30 1 13 3.3%
salm[1st intron-dsRed] Act5C-Cas9, Lig42/2 sgRNA3 + sgRNA4 700 200 122 64 9 54 14.1%
salm[3rd exon-dsRed] Act5C-Cas9, Lig42/2 sgRNA7 + sgRNA9 700 291 150 99 4 59 4.0%
bent Act5C-Cas9, Lig42/2 bent -sg1 + bent -sg3 700 204 118 56 1 5 1.8%
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Step 2: Flexible gene editing by RMCE
A major benefit of our editing strategy is the flexible step 2 that enables
the near-seamless insertion of any DNA sequence with only two
remaining attR sites (Figure 1). To test the feasibility of step 2, we chose
the salm[1st intron-dsRed] allele. We exchanged the STOP-dsRed cassette
with a short 2xTY1-V5 exon, a FRT-2xTY1-FRT-V5 conditional exon,
and a large GFP-3xFLAG exon from Venken et al. (2011) (Figure 4B).
As expected, in all three cases the cassette exchange worked routinely
and, typically, injection of approximately 200 embryos is sufficient to
obtain two or more RMCE events in the correct orientation (see
Materials and Methods). Importantly, the salm[1st intron-dsRed] le-
thality was reverted by RMCE in all three cases (Figure 5B). This
demonstrates that our editing protocol generally does not result in
any unwanted lethal mutations on the edited chromosome.
Salm protein is expressed in indirect flight muscles (IFMs) and is
essential for fibrillar IFM fate specification (Schönbauer et al. 2011).
Thus, we should detect the tagged Salm protein versions in the IFM
nuclei of adult flies. Tagged protein from all three alleles, salm[1st intron-
TY1-V5], salm[1st intron-FRT-TY1-FRT-V5], and salm[1st intron-GFP-
FLAG] is expressed in IFMs. Salm-TY1-V5 and Salm-GFP-FLAG are
readily detected in the IFM nuclei, and Salm-FRT-TY1-FRT-V5 shows
an additional dotty pattern in the cytosol, which might be caused by the
FRT sequence translated into protein (Figure 5C–G). The fibrillar IFM
morphology is normal in all three homozygous salm alleles, showing
that the tagged Salm proteins are indeed functional. Each IFM fiber
contains several hundred nuclei. The conditional salm[1st intron-FRT-
TY1-FRT-V5] should now enable a clonal loss-of-function analysis of
salm in muscle only, as flip-out in cis is highly efficient (Hadjieconomou
et al. 2011). Thus, this strategy should generally be versatile for the
genetic analysis of muscle in the future.
Gene editing on the fourth chromosome
To demonstrate the general applicability of our gene editing strategy,
we decided to apply it to an additional locus. We chose the bent gene,
located on chromosome four, which is highly heterochromatic and
thus difficult to manipulate by standard genetic tools. To our knowledge,
there is only a single case reported in the literature that targeted a gene
located on the fourth chromosome by classical ends-out mediated
Figure 5 Phenotypic analysis of the engineered salm alleles. (A) Lethality assay of the salm-dsRed alleles as homozygous or in trans to salm[1]. (B)
All tagged salm[1st intron] alleles regain homozygous viability after step 2. (C–G) Localization of the tagged Salm proteins. Untagged Salm is
located in the nucleus of wild-type IFMs (C, E), whereas V5 tagged Salm is only detected in the salm[1st intron-TY1-V5] and the salm[1st intron-FRT-
TY1-FRT-V5] alleles (D, G). FLAG is found in the IFM nuclei of salm[1st intron-GFP-FLAG] adults (F). The Salm-FRT-TY1-FRT-V5 protein is found in
the nuclei (red arrow heads) and also located in dots in the cytoplasm (G). Note the normal fibrillar morphology of the myofibrils in all the
homozygous salm[1st intron] alleles (D, F, G). Actin was stained with phalloidin and the scale bars are 10 mm.
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homologous recombination using long homology arms (Rodriguez-
Jato et al. 2011). bent is a very large gene composed of at least 46 exons
that are spread across more than 51 kb of genomic DNA (Figure 6).
bent encodes for Projectin, a titin-like protein that is specifically
expressed in muscles and essential for correct sarcomeric organization
(Fyrberg et al. 1992; Ayme-Southgate et al. 1995; Schnorrer et al. 2010).
It is supposedly silent in germ cells, in which the targeting event must
happen. We chose to delete exon 11, an exon at the beginning of the
PEVK domain of Projectin (Ayme-Southgate and Southgate 2006), using
two sgRNAs flanking the exon. Both sgRNAs tested positively in the S2
cell assay (data not shown). We again used approximately 1 kb homol-
ogy arms and injected the donor vector into 700 Act5C-Cas9, Lig4[169]
embryos. We isolated five carriers from 1 founder out of a total of
56 fertile G0 flies, resulting in an HDR efficiency of 1.8%. We confirmed
the bt[11th intron-dsRed] allele by sequencing of the locus. As expected,
bt[11th intron-dsRed] is homozygous lethal and also lethal in trans to
bt[I-b], a strong bent allele (Ayme-Southgate et al. 1995), again suggest-
ing that the inserted splice acceptor is used effectively and transcription
is prematurely terminated. Together, these results demonstrate that our
CRISPR-mediated targeting strategy also works efficiently on the fourth
chromosome, suggesting it can be generally applied to any locus of
choice in the fly genome.
DISCUSSION
CRISPR/Cas9 has been used successfully in many model organisms to
generate mutants or to introduce targeted changes by HDR (Hsu et al.
2014). In Drosophila, there has been no general agreement regarding
which strategy works most effectively to engineer the genome. To simply
mutate a gene by CRISPR/Cas9-induced NHEJ, Cas9 was either injected
as mRNA (Bassett et al. 2013; Yu et al. 2013), provided from an injected
plasmid (Gratz et al. 2013a; Baena-Lopez et al. 2013), or provided from
a transgenic source (Kondo and Ueda 2013; Ren et al. 2013; Sebo et al.
2014). Similarly, the sgRNA was either injected as in vitro transcribed
sgRNA or provided by an injected plasmid or a transgenic source. A
standard protocol has not yet emerged, although several genes have been
mutated.
NHEJ can only induce small insertions or deletions. In contrast,
HDR allows the defined engineering of a given gene and thus is suitable
for a much wider range of applications. CRISPR/Cas9-mediated HDR
has been used in Drosophila to insert short attP or tag sequences from
single-strand oligonucleotides as donors (Gratz et al. 2013a) or larger
cassettes including a dsRed marker cassette from a plasmid donor
(Baena-Lopez et al. 2013; Yu et al. 2014; Gratz et al. 2014; Xue et al.
2014), again using various ways of injected or transgenic sources of
sgRNAs or Cas9. The injected genotype was variable; sometimes Lig4
mutants were used (Baena-Lopez et al. 2013; Yu et al. 2014; Gratz et al.
2014; Xue et al. 2014), sometimes they were not used (Baena-Lopez
et al. 2013; Yu et al. 2014; Gratz et al. 2014; Xue et al. 2014; Gokcezade
et al. 2014; Port et al. 2014). Often the detection of the targeted event
required laborious fly screening by PCR (Gratz et al. 2013b; Yu et al.
2014; Gokcezade et al. 2014).
Here we aimed to develop a universal and efficient CRISPR-based
strategy that enables flexible genome engineering, including the insertion
of large tags into the coding region of a gene or the generation of
conditional alleles. This strategy should be generally applicable to most
Drosophila genes. Our results confirmed that approximately 1-kb ho-
mology arms are of sufficient length to insert a large marker cassette, as
has been suggested before for other loci (Gratz et al. 2014; Yu et al. 2014;
Xue et al. 2014; Port et al. 2014). Thus, we could develop an efficient
donor plasmid assembly protocol that facilitates cloning of the donor
vector for any gene within a few days. Additionally, our data support the
value of a quick pretesting strategy of predicted sgRNAs in S2 cells to
eliminate inefficient sgRNAs, which would likely reduce targeting effi-
ciency in vivo. However, we have not tested how well sgRNA efficiencies
in S2 cells correlate with efficiencies in vivo. Conveniently, the same
in vitro transcribed RNAs can be used for both S2 cell transfections
and embryo injections. Our results suggest that a transgenic Cas9 source
mediates HDR effectively in Ligase4 mutant germline cells. Although
Act5C-Cas9 expression is not restricted to the germline, injections of the
donor vector together with two verified sgRNAs led to a targeting effi-
ciency of 2%–14% of fertile G0 flies for the incorporation of the large
STOP-dsRed cassette, even for the bent locus on the heterochromatic
fourth chromosome. This suggests that approximately 50–100 fertile G0
flies should be sufficient in most cases to identify positive carriers. We
and others (Gokcezade et al. 2014) have observed relatively high de-
velopmental lethality of the injected G0 flies, which might be caused by
somatic knock-out of the targeted gene. Thus, survival rate of the
injected embryos and larvae might be increased when using a germ-
line-restricted Cas9 source, such as nos-Cas9. However, nos-Cas9 was
reported to be less efficient in germline transmission compared with
Act5C-Cas9 (Port et al. 2014). We thus far have deleted up to approx-
imately 1 kb of genomic sequence by HDR. Larger deletions would likely
occur at reduced efficiencies; however, the dsRed marker should still
make it practical to find them. The straightforward identification of
carriers together with our simple cloning scheme should easily facilitate
the insertion of the STOP-dsRed cassette into the gene of choice.
Recent reports using a transgenic sgRNA source (Port et al. 2014)
or an injected sgRNA source (Ren et al. 2014) report very effective
Figure 6 Engineering of the bent
gene. The entire genomic bent
organization is shown at the top
with a 10-kb zoom-in below. Cod-
ing exons are in orange. The
sgRNA targeting sites flanking
exon 11 are indicated by red
arrows and the resulting bent
[11th exon-dsRed] allele is shown
at the bottom.
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HDR rates with more than 50% of the fertile G0 flies being positive
founders and, thus, screening by PCR-based methods were practical in
these cases. However, both studies used only a single locus to insert
the GFP tagging cassette; hence, a direct comparison with the efficien-
cies that we report here is difficult.
Our two-step strategy combines the advantages of both CRISPR
and RMCE, thus allowing very flexible modifications of a particular
gene region with minimal effort. Multiple fluorescent and affinity tags
can be easily inserted or a deleted exon can effectively be replaced by
various engineered exon versions. In principle, larger gene parts con-
sisting of multiple exons can also be deleted and replaced by modified
versions. This method is particularly valuable for genes that harbor
complex transcriptional control and function in many tissues such as
salm or for genes that are exceptionally large and exhibit complex
alternative splicing patterns such as bent. The two-step strategy allows
structure–function analysis at the endogenous locus without interfering
with the regulatory regions included in introns, which cannot be
achieved by simply inserting a cDNA at the transcriptional start site.
The functionality of our method was verified by the reversion of the
lethality for the step 2 alleles in the first intron of salm. This furthermore
suggests that both steps do not generate additional unintended changes
on the chromosome. Therefore, we hope that our strategy will promote
the wide application of CRISPR-mediated HDR in Drosophila, making
it a routine tool used in every fly laboratory like EMS mutagenesis or
P-element–mediated transformation was in the past century.
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